linjc16/ctgov huggingface dataset:
Trend in Hospital Lengths of Stay and Readmissions

Study Overview
=================
Brief Summary
-----------------
Medical and surgical innovations have allowed to shorter length of hospital stay (LOS). We assume that hospitals with uncontrolled reduction in LOS may expose patients to unsafe care. At the institutional level, a dynamic analysis of LOS evolution over time could clarify the existence of a link with the risk of readmission.

Official Title
-----------------
Association Between Trend in Length of Stay and Risk of Readmission at Hospital After Surgery

Conditions
-----------------
Trend in Hospital Lengths of Stay and Readmissions

Intervention / Treatment
-----------------
* Other: Hospital stay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who underwent elective colorectal surgery or urgent surgical procedure for hip fracture in French public and private hospitals from January 2014 to December 2016 Exclusion Criteria: Age < 18 years old Death during the index stay

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colorectal surgery<br>Patient who underwent elective colorectal surgery | Other: Hospital stay<br>* Collection of hospital lengths of stay and readmissions<br>|
| Hip fracture<br>Patient who underwent urgent surgical procedure for hip fracture | Other: Hospital stay<br>* Collection of hospital lengths of stay and readmissions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unplanned hospital readmission with death, intensive care, or reoperation | Number of unplanned hospital readmission with death, intensive care, or reoperation within 30 days of surgical procedure | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unplanned hospital readmission with death, intensive care, or reoperation | Number of unplanned hospital readmission with death, intensive care, or reoperation within 3 months of surgical procedure | 3 months | 
| Unplanned hospital readmission with death, intensive care, or reoperation | Number of unplanned hospital readmission with death, intensive care, or reoperation within 6 months of surgical procedure | 6 months |
Risk Scoring Systems in Upper GI-haemorrhage

Study Overview
=================
Brief Summary
-----------------
Use of risk scoring systems in the assessment of patients presenting with upper gastrointestinal haemorrhage is increasing. Comparative studies have intended to identify the system of choice, but the majority of these are characterized by retrospective designs, small sample sizes, low rate of severe bleeding, or low mortality. The main aim of this study was to identify the optimal scoring system.

Official Title
-----------------
Risk Scoring Systems in Upper GI-haemorrhage

Conditions
-----------------
Upper Gastrointestinal Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: One of the following: Haematemesis Melaena Coffee-ground vomit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need for hospital-based intervention | Need of hospital-based intervention was defined as treatment with blood transfusion, endoscopic therapy, transcatheter arterial embolization (TAE), surgery, or identification of cancer at upper endoscopy. | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of low-risk patients | Low-risk patients were defined as patients who did not need hospital-based intervention, and survived more than 30 days from day of admission. Low-risk patients were considered as suitable for early discharge and potential outpatient management. | 1 month | 
| Rebleeding | Rebleeding was defined as presence of hematemesis, blood per nasogastric tube, or melaena associated with a decline in B-hemoglobin of at least 1mmol/l (not explained by hemodilution) or decline in systolic arterial pressure of at least 20mmHg after the initial bleeding had stopped. | 1 month | 
| 30 day mortality |  | 30 days |
Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology

Study Overview
=================
Brief Summary
-----------------
This is an open, prospective, controlled, randomized, comparative study with 2 arms. The purpose of the study is to assess the efficacy of osteopathy after breast surgery. 80 patients will be enrolled, 40 per arm. Patients will be randomized at inclusion and will be followed during one year.

Official Title
-----------------
Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: OSTEOPATHY + conventional analgesic treatments
* Other: Conventional analgesic treatments


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: woman >= 18 years pain (median VAS >=3 on the week prior to inclusion) mastectomy or tumorectomy with axillary dissection <= 12 months PS <=2 able to write, understand and read French signed informed consent Exclusion Criteria: no pain immediate breast reconstruction history of cognitive or psychiatric troubles

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: osteopathy + conventional analgesic treatments<br> | Other: OSTEOPATHY + conventional analgesic treatments<br>* 5 sessions for osteopathy are planned and will start in the 15 days following the enrollment. The conventional analgesic treatments will be administered in the 15 days following the enrollment.<br>|
| Placebo Comparator: conventional analgesic treatments<br> | Other: Conventional analgesic treatments<br>* These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of the osteopathy treatment on pain | Pain is assessed by means of visual analogic scale (from 0 to 10 points). A decrease of 2 points after 3 months is expected. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteopathy, Breast cancer, Pain
Trans-abdominal Fetal Pulse Oximetry: Signal Integrity

Study Overview
=================
Brief Summary
-----------------
This project is set up to advance and integrate the established mathematical principles of oxygen saturation to model with increasing accuracy the body in a body problem of fetus in mother; similar to existing pulse oximeters,

Detailed Description
-----------------
The investigational device is a non-invasive fetal pulse oximeter that measures fetal arterial pulse signal using safe, noninvasive, transabdominal near-infrared spectroscopy. The optical sensor will obtain fetal pulse oximetry signals. Women will also undergo sonographic evaluation to assess distance from maternal skin to fetal tissue and to confirm fetal presentation and position. There is no change to standard of care procedures for fetal heart rate monitoring. The fetal heart rate that will be monitored with the investigational device will be used for research purposes only. Results will not be used to guide or alter patient management.

Official Title
-----------------
Trans-abdominal Fetal Pulse Oximetry: Signal Integrity

Conditions
-----------------
Fetal Distress

Intervention / Treatment
-----------------
* Device: Raydiant Oximetry Sensing System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with singleton pregnancies, vertex presentation Age ≥ 18 years Healthy women ≥ 28 weeks gestation undergoing either Non-Stress test (NST) or Biophysical profile (BPP) OR Healthy women ≥ 37 weeks in labor Vertex presentation Exclusion Criteria: Age <18 years Multiple gestation ( twins, triplets) Presentation other than vertex < 28 weeks of gestation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Clinic<br>This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP) | Device: Raydiant Oximetry Sensing System<br>* The investigational device is used to record fetal pulse signals.<br>* Other names: ROSS;|
| Labor and Delivery<br>This group is in active labor. | Device: Raydiant Oximetry Sensing System<br>* The investigational device is used to record fetal pulse signals.<br>* Other names: ROSS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal signal integrity | Integrity of the fetal signal relative to background maternal signal and biologic/electronic noise, and related to fetal position, presentation and the depth of the fetus from maternal skin. | During NST, BPP, or active labor |
Endotracheal Tube (ETT) Cuff Pressure Study in the Emergency Department (ED)

Study Overview
=================
Brief Summary
-----------------
Our study will measure the pressure of the endotracheal tube cuff in intubated patients in the emergency department.

Detailed Description
-----------------
Although manometers are available for the purpose of measuring ETT intra-cuff pressures, they are not currently in use at our institution's Emergency Department. This prospective cohort study will endeavor to determine the incidence of unacceptably high ETT cuff pressures in the ED, laying the foundation for follow up studies on patient outcomes and the potential need for more careful management of intra-cuff pressures in the ED.

Official Title
-----------------
Endotracheal Tube Cuff Pressure in the Pediatric Emergency Department: A Pilot Study

Conditions
-----------------
Endotracheal Tube Cuff Pressure Pediatric Emergency

Intervention / Treatment
-----------------
* Device: Cuffed ETT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cuffed ETT in place on arrival in the ED cuffed ETT placed while in the ED Exclusion Criteria: ETT cuff electively left deflated by practitioner Uncuffed ETT used
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cuffed ETT<br>Patients that are intubated with a cuffed endotracheal tube. | Device: Cuffed ETT<br>* Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cuff pressure | One measurement of the ETT cuff pressure after intubation in the emergency department. | One time in the ED prior to discharge to the ICU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intubation, cuff, cuffed, endotracheal, tube, pressure, pediatric, child, children, emergency
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).

Detailed Description
-----------------
Healthy adult volunteers are assigned randomly to either a vaccine or placebo group. Injections are received either intramuscularly, intradermally, or by delivery under the skin of the volunteer's own white blood cells which have had dendritic cell reinfusion. Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week post-immunization. Volunteers undergo leukopheresis at the start of the study and after the last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation benefits.

Official Title
-----------------
A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly

Conditions
-----------------
HIV Infections, HIV Seronegativity

Intervention / Treatment
-----------------
* Biological: ALVAC-HIV MN120TMG (vCP205)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Volunteers may be eligible for this study if they: Are legal US residents. Are healthy adults from 18 to 55 years of age. Exclusion Criteria Volunteers will not be eligible for this study if they: Are HIV-positive. Are at highest risk for HIV infection. Are pregnant or breast-feeding. Are allergic to eggs or neomycin. Use certain prescription medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: ALVAC-HIV MN120TMG (vCP205)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-1, Injections, Intramuscular, Injections, Intradermal, Injections, Subcutaneous, AIDS Vaccines, Dendritic Cells, HIV Seronegativity, Genes, env, Genes, pol, Genes, gag, Transfection, HIV Preventive Vaccine
Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

Study Overview
=================
Brief Summary
-----------------
The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.

Official Title
-----------------
A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

Conditions
-----------------
High Altitude Pulmonary Edema

Intervention / Treatment
-----------------
* Drug: Acetazolamide
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Able to consent English speaking Trekking directly to Everest Base Camp Exclusion Criteria: Age less than 18 years Non-English speaking Pregnant Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema Been on a high-altitude trek 2 weeks prior to this study Has taken acetazolamide 1 week prior to start of trek Has a sulfa allergy Has any type of acute or chronic pulmonary conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acetazolamide normal dose<br>One (1) dose of 250mg of Acetazolamide | Drug: Acetazolamide<br>* Administration of Acetazolamide<br>* Other names: diamox;|
| Placebo Comparator: Placebo<br>One (1) dose of placebo | Drug: Placebo<br>* Administration of Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary Edema Before and After Taking Acetazolamide | Edema measured through ultrasound exam | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Completion of Ultrasound Exams | Time it takes to complete ultrasound exams | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acetazolamide, High-altitude illness, High-altitude pulmonary edema, Lung comets, Lung ultrasound, Subclinical high-altitude pulmonary edema
CT Scores Predict Mortality in 2019-nCoV Pneumonia

Study Overview
=================
Brief Summary
-----------------
While 2019-nCoV nucleic acid swab tests has high false positives rate, How to diagnose 2019-nCoV pneumonia and predict prognosis by CT is very important.In this retrospective single-center study, we consecutively included suspected 2019-nCoV pneumonia critical cases in the intensive care unit of Wuhan third hospital from January 31, 2020 to February 16, 2020. The cases were confirmed by real-time RT-PCR, and all patients were evaluated with CT, cutoff values were obtained according to the Yoden index, and were divided into high CT score group and low CT score group. Epidemiological, demographic, clinical, and laboratory data were collected.

Official Title
-----------------
CT Scores Predict Mortality in 2019-nCoV Pneumonia

Conditions
-----------------
CT Scores Predict Mortality in 2019-nCoV Pneumonia

Intervention / Treatment
-----------------
* Other: CT score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients suspected of 2019 novel coronavirus infection. Exclusion Criteria: patients' data are not available.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High CT score<br> | Other: CT score<br>* CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3<br>|
| Low CTscore<br> | Other: CT score<br>* CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 7-day mortality |  | 7-day |
Self-management for People With Epilepsy and a History of Negative Health Events

Study Overview
=================
Brief Summary
-----------------
This is an investigation of adult individuals with epilepsy, and involves educational and behavioral interventions intended to enhance treatment adherence and self-management. The investigators are adapting a self-management intervention that they developed in a previous study to individuals with epilepsy and a history of negative health events (NHEs), such as accidents and emergency department (ED) visits, diminished quality of life and poor mental well-being. The intervention Self-management for people with epilepsy and a history of negative health events (SMART) is intended to reduce NHEs and improve quality of life in people with epilepsy associated with historically disadvantaged groups.

Official Title
-----------------
Self-management for People With Epilepsy and a History of Negative Health Events (SMART)

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Behavioral: self-management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of epilepsy Negative health event within the last 6 months Able to provide written consent and participate in study procedures Exclusion Criteria: Immediate risk of self-harm Dementia Pregnancy Unable to read/understand English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: SMART Intervention<br>Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio. | Behavioral: self-management<br> <br> |
| Active Comparator: Wait-list<br>Participants assigned to the wait-list will start the SMART intervention 6 months following randomization. | Behavioral: self-management<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in number of negative health events |  | baseline, 6 months |